In the News

Thousands of technology professionals from around the world recently gathered in Long Beach, California, for the sold-out Neural Information Processing Systems (NIPS) conference, a multi-track machine learning, artificial intelligence, and computational neuroscience event featuring talks, demonstrations, symposia and oral / poster presentations, along with several workshops. Leaders in artificial intelligence, machine learning, and data engineering from Memorial Sloan Kettering attended NIPS and announced the winner of a unique competition created by MSK, Classifying Clinically Actionable Genetic Mutations. For more information and to set up interviews or access photos and video, email [email protected].

SummaryMore than 20 MSK physicians and researchers presented work at an annual breast cancer conference in San Antonio.The San Antonio Breast Cancer Sy...

In the largest-ever genetic analysis of people being treated with checkpoint inhibitors, Memorial Sloan Kettering researchers looked at patients who received several checkpoint inhibitors for a number of different cancers at many different hospitals. Researchers found that people who had a greater diversity and more variation in their human leukocyte antigen (HLA) genes responded much better to immunotherapy compared with those who had less diversity. For more information or to speak with an expert, contact Rebecca Williams at [email protected].

Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.

Dose-dense chemotherapy calls for less time between doses compared with a standard treatment plan.

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising early-career investigators.

MSK investigators are learning how cancer cells escape from the original tumor and hide out in the body. Their goal is to prevent metastatic tumors from forming.

Meet Christine Iacobuzio-Donahue, a physician-scientist who studies cancer metastasis and is collaborating on genetics research with scientists at the American Museum of Natural History.

A team led by MSK molecular biologist Scott Lowe is making progress against fibrolamellar hepatocellular carcinoma.